Supported by

Catalogue of collaboration profiles

back to list
Company

PRAXI / HELP-FORWARD Network &The Hellenic BioCluster

Street
Zalokosta 4
ZIP Code
10675
City
Athens
Country
Greece


Company Profile:
PRAXI / HELP-FORWARD Network is a technology transfer organization addressed to small and medium sized enterprises and research institutions all over Greece. Its services range from information to mediation and advisory support, covering the whole spectrum of activities related to research collaboration, technology transfer and commercial exploitation of research results.

PRAXI stimulates competitiveness of Greek enterprises and research institutions via linking research and industry, promoting innovation and entrepreneurship as well as transnational cooperation.

Within this role, PRAXI is the coordinator of the Greek consortium of the Enterprise Europe Network (Enterprise Europe Network - Hellas), which provides international business cooperation services, information on European policies, innovation and technology transfer services as well as services for encouraging SME' participation to the European programs for Research and Technology.

PRAXI is also the animator of the Hellenic BioCluster, a coalition of Greek Life Sciences companies, encompassing corporate players in the sectors of Biotechnology, Diagnostics, Medical Devices, Pharmaceuticals and Services.


Profiltitel

The Hellenic BioCluster (HBio)

What we offer:
The Hellenic BioCluster (HBio) in Athens, is a coalition of Greek Life Sciences companies, encompassing corporate players in the sectors of Biotechnology, Diagnostics, Medical Devices, Pharmaceuticals and Services. HBio now has 23 member companies and 3 leading research institutions as associate members.

HBio aims to support the promotion of the Greek Life Sciences business sector and facilitates international business & research collaborations. It offers contacts with Life Science companies and organisations in Greece for technical co-operation, commercial agreements, collaboration in R&D and other forms of joint venture.

The Hellenic BioCluster members can be found in the following link: http://www.hbio.gr/members_profiles.shtml

What are we looking for:
We are looking for potential partners interested in doing business in Greece and/or establishing business collaboration agreements with Greek organisations.

Collaboration sought:
  • Research & Development
  • Technical Co-operation
  • Joint Venture Agreement
  • Manufacturing Agreement
  • Licence
  • Commercial Agreement


Responsible

Despina Yancopoulou

Technology Transfer Consultant - Life Sciences
Profiltitel

Cytogenetic and molecular testing services for pharma and biotech companies

What we offer:
A Greek biotechnology company offers unique expertise in classical and molecular cytogenetics and molecular genetics testing (oncology, infectious diseases, human genetic diseases). Partner companies can benefit from high quality assurance, lower cost and services customisation.

The services can be offered under a technical cooperation or sub-contracting agreement. This is of interest to pharmaceutical and biotechnology companies who outsource their clinical trials testing, as well as to healthcare organizations and healthcare professionals who need to outsource diagnostic testing.

What are we looking for:
1) Pharmaceutical and biotechnology companies with novel therapeutic and diagnostic products/ technologies which need to outsource pharmaceutical trials and marketing trials

2) Healthcare organisations and healthcare professionals that outsource diagnostic testing

Collaboration sought:
  • Research & Development
  • Technical Co-operation
  • Commercial Agreement


Responsible

Despina Yancopoulou

Technology Transfer Consultant - Life Sciences
Profiltitel

Transgenic mouse models for preclinical drug evaluation in autoimmune and inflammatory diseases

What we offer:
A Greek contract research organization (CRO) provides pre clinical drug evaluation models and services in autoimmune and inflammatory diseases. The company provides its services to biopharmaceutical companies using unique, humanized, spontaneous, and complex disease animal models.

The company’s scientific team are distinguished researchers with unique expertise in the field of immunological diseases who have been providing their expertise and consultancy to pharmaceutical companies for over 10 years.

The company can either supply the transgenic models directly to interested pharma/biotech companies or perform the preclinical and other tests in house, as appropriate.

In addition to the services currently available, the company is engaged in generating additional novel humanized disease models to meet the needs of the pharmaceutical industry in autoimmune and inflammatory diseases. To this end the company is willing to discuss client customised needs in pre-clinical drug testing.

The company is looking for pharma and biotech partners who need pre-clinical drug evaluation services to support their drug development efforts, for technical and commercial agreements.

What are we looking for:
Biotech/pharma companies which need to test novel drugs in autoimmune and inflammatory diseases.

Collaboration sought:
  • Research & Development
  • Technical Co-operation
  • Commercial Agreement


Responsible

Despina Yancopoulou

Technology Transfer Consultant - Life Sciences
Profiltitel

Infusion pumps and telemedicine systems

What we offer:
A Greek company is developing infusion pumps and telemedicine systems, with worldwide distribution. The technologies enable patient monitoring whilst on the move and new ways of delivering and monitoring drugs. The company specializes in ambulatory and home care treatment.

Novel technologies
- Telemedicine application. The application allows ambulatory patients to report on therapeutic and side effects of their therapy and also allows adjustment of therapy remotely.
- New catheter & pump system FLU-X™. The technology is intended to be used for fluid exchange (infusion and evacuation of fluids and drug solutions) in patients with septic trauma, haematoma and abscess, as well as for immediate post-operative intratumoral chemotherapy of malignant tumors, including intracranial ones. The system will be CE marked by the end of 2010. This is a new delivery route for drugs which provides unique therapeutic benefits to patients.
- Novel diabetes care system. A disposable patch with an insulin pump and a self-calibrating CGMS. The accuracy of the enzymatic glucose sensor is very high, so that closed loop infusion will be possible in the future. The system is conceived for distribution through pharmaceutical channels, as a single use, all- in-one pre-filled system, similar to the way strip readers are sold today.

What are we looking for:
CROs or pharmaceutical companies that need the above new way to organize clinical trials, and develop drugs in a Personalized Medicine context.

Pharmaceutical companies that need a new delivery system for a patent.

Pharmaceutical companies in the diabetes healthcare market.

Collaboration sought:
  • Technical Co-operation
  • Manufacturing Agreement
  • Commercial Agreement


Responsible

Despina Yancopoulou

Technology Transfer Consultant - Life Sciences
Profiltitel

Novel drug for metastatic neuroendocrine cancer

What we offer:
A Greek SME is looking for partners across Europe, Russia and Turkey for distribution of a novel drug for metastatic neuroendocrine cancer.

The opportunity has important market potential. The novel drug (designated as an Orphan Drug by EMEA) is a treatment for metastatic carcinoid and pancreatic neuroendocrine tumors, in patients whose symptoms are not controlled by conventional therapy. There is no other drug approved with such indication.

The drug has been initially developed by Novartis (Clinical Phases I and II) and now the Greek SME has acquired the rights for Phase III clinical development that leads to Marketing Authorization (Registration). Phase III clinical trials have been approved by the European Medicinal Agency (EMEA) and are underway.

In addition, EMEA allows and recognizes compassionate use of unregistered drugs: patients should have early access to unregistered drugs if this is to cover unmet clinical needs and the drugs have finalized Phase II (Official EMEA Guideline). These requirements are fulfilled by the novel drug in question, which is already being distributed for compassionate use, before the completion of clinical trials (Phase III).

What are we looking for:
The company is looking for partners for distribution and sales across Europe. Ideal partners are companies with very good access to local oncology hospitals and clinics. Partners will benefit from exclusive distribution agreements in the specified geographic locations.The opportunity has an excellent commercial potential, which can be discussed with interested partners.

Collaboration sought:
  • Commercial Agreement


Responsible

Despina Yancopoulou

Technology Transfer Consultant - Life Sciences
Profiltitel

Request for novel phase III pharmaceuticals

What we offer:
A Greek pharmaceutical company is seeking to in-license novel phase III pharmaceuticals or pharmaceuticals at pre-registration phase.

The pharmaceutical products to be in-licensed, can address various fields, such as: gastro-enterology, cardiovascular diseases, vertigo & vomiting, dermatology, oncology, analgesics-inflammation, haematology, respiratory.

The company aims to commercialize and market these products in the Greek and/or other neighbouring markets (Cyprus and Balkan countries).

What are we looking for:
Biotech companies with novel pharmaceuticals at phase III or pharmaceuticals at pre-registration phase. The partners offering the pharmaceutical products for in-licensing should be distinguished in their fields and the pharmaceutical products should meet strict quality criteria.

Responsible

Despina Yancopoulou

Technology Transfer Consultant - Life Sciences
back to list

Participants

Enterprise Europe ScotlandAboleo LtdAccuro BiologicsAlliance BootsBeta TechnologyBitWiseFW Medical LLPInnova Partnerships LtdInterface-The knowledge connection for businessMarks and Clerk LLPMcClure Naismith LLPThe Medical Device Company LtdQuantics Consulting LtdScottish Health InnovationsPharmalinksSistemic LtdStrathclyde Institute of Medical DevicesSynthetic Nanomachines LtdTissue SolutionsUniversity of AberdeenEllis IP LtdPharmacells LtdCeltic CatalystsPharmaceutical eConsultingWeatherologyControlled TherapeuticsSphere Fluidics LimitedHighland Clinical Research FacilityMoorfields PharmaceuticalsEdinburgh Science Trianglebeocarta LtdRostiShore DesignPomBioTech GmbHIMG Innovations-Management  GmbH/ Enterprise Europe NetworkThe Eurotactics ConsultancyIBA GmbHSGS Life Science ServicesOnorach  ClinicalWideblueEnterprise Europe YorkshireAptuit ConsultingMosaigen/Endeavour CapitalEscubed LtdEulysis Ltd.Raumedic LtdCatalent Pharma SolutionsEscubed LtdUniversity of Aberdeen Research and InnovationSPRI - Basque Enterprise Europe NetworkLicentia LtdTake The WindRoslin CellabMoredun ScientificEnterprise Europe East of EnglandAvantiCell ScienceXeroshield Ltd.ImmunoSolv LimitedLeoben Research LimitedPRAXI / HELP-FORWARD Network &The Hellenic BioClusterEMBIO Diagnostics Ltd


© 2010 ConVerve GmbH | all rights reserved